Sloane Vision Center Acquires Newest Laser Vision Correction Platform in Mid-West.

WaveLight's Eye-Q Is Fastest LASIK System in the Country

CHICAGO -- Sloane Vision Center announced today that it is the first LASIK institution in the Mid-West US to acquire the new ALLEGRETTO WAVE([R]) Eye-Q system, sold by WaveLight, Inc. Featuring advanced Wavefront Optimized[TM] technology that has been available at Sloane Vision Center for more than three years, this next generation platform provides the fastest LASIK treatments available today.

"This world-leading laser vision correction system allows us to provide the same precise and predictable visual results that our patients have come to expect from Sloane Vision Center, in less time than ever before," said Herman Sloane, MD, FACS, Medical Director of Sloane Vision Center. "With its wide range of FDA approvals, amazing speed, accuracy and reliability, no other laser offers the advantages of the Eye-Q."

The Eye-Q system, manufactured by WaveLight AG, corrects one diopter of nearsightedness or farsightedness in just two seconds. Therefore, the average treatment time to complete the LASIK procedure is typically between just eight and ten seconds. Shorter treatments have been shown to potentially improve the accuracy of corrections after LASIK and reduce the likelihood of infections. In addition, patient comfort is enhanced as the amount of time required to focus during the procedure is significantly reduced.

This next generation system features WaveLight's proprietary PerfectPulse Technology(TM) to ensure maximum safety at high speeds. PerfectPulse Technology was specifically developed to monitor and control each laser pulse that is delivered to the cornea during the LASIK procedure. Another component of this technology is a high speed, active eye-tracking device which monitors eye movement 400 times per second and adjusts the laser beam accordingly in less than six milliseconds.

The Eye-Q also features WaveLight's proprietary Wavefront Optimized[TM] technology, which has been shown to preserve the natural shape of the cornea and prevent the induction of optical errors that could lead to night vision problems or loss of contrast sensitivity (the ability to see the images crisply).

"Dr. Herman Sloane was one of WaveLight's first US customers to acquire the ALLEGRETTO WAVE([R]) nearly three years ago and now he is setting the same precedent with the adoption of the newest and fastest LASIK platform approved in the US," said Wolfgang Tolle, CEO of WaveLight, Inc. "We are honoured to continue our partnership with Dr. Sloane, given his clinic's reputation for providing excellent patient care and his commitment to leadership in refractive surgery."

About Sloane Vision Center

Located in Oak Brook, Illinois, just west of Chicago, Sloane Vision Center offers the widest range of vision correction procedures available. Medical Director Herman D. Sloane, MD, FACS is a highly qualified, board-certified, ophthalmic surgeon and one of the most experienced vision correction surgeons in the Chicago area.

Since 1985, Dr. Sloane's patients have expressed their confidence in the fact that he has led the way in advances in vision correction surgery. As one of the few fellowship-trained refractive surgeons and a participant in some of the earliest clinical research studies for excimer laser vision correction surgery, Dr. Sloane has utilized virtually every laser available and has chosen the high performance vision available with the ALLEGRETTO WAVE([R]) by WaveLight.

WaveLight AG (ISIN DE 000 512 5603)

WaveLight AG has been listed on Deutsch Borse AG's Prime Standard segment since January 2003: The company, which develops, manufactures and markets a full range of high-quality products for ophthalmology, specializes in vision optics. The market success of WaveLight is based on a dense sales network comprised of WaveLight's own sales channels as well as the sales channels of strategic partners.

Further information on WaveLight is available at: www.wavelight.com/eyes

All information is given and all assessments are made on the basis of extremely conscientious research. However, no guarantee is given with regard to the information or assessments published. No liability whatsoever is accepted. The above statements do not represent an invitation to buy or sell securities. All rights reserved.

Disclaimer for Myopia:

a. Approval of the premarket approval application is for the WaveLight ALLEGRETTO WAVE[R] Eye-Q Excimer Laser System to perform LASIK treatments in patients 18 years of age or older for the reduction or elimination of myopic refractive errors up to -12.0 diopters (D) of sphere with and without astigmatic refractive errors up to -6.0 D; and in patients with documented evidence of a stable manifest refraction defined as [?] 0.50 D of preoperative spherical equivalent shift over one year prior to surgery.

b. LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), and other refractive surgeries.

c. Approval of the application is based on clinical trials in the United States with 901 eyes treated, of which 813 of 866 eligible eyes were followed for 12 months. Accountability at 3 months was 93.8%, at 6 months was 91.9%, and at 12 months was 93.9%.

d. The studies found that of the 844 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 3-month stability time point, 98.0% were corrected to 20/40 or better, and 84.4 % were corrected to 20/20 or better without spectacles or contact lenses.

e. The clinical trials showed that the following subjective patient adverse events were reported as "moderate to severe" at a level at least 1% higher than baseline of the subjects at 3 months post-treatment: visual fluctuations (12.8% at baseline versus 28.6% at 3 months).

f. Long term risks of LASIK for myopia with and without astigmatism beyond 12 months have not been studied.

g. Note that the complete name for this ophthalmic laser is "WaveLight ALLEGRETTO WAVE[R] Eye-Q Excimer Laser System for laser assisted in situ keratomileusis (LASIK) treatments of myopic refractive errors up to -12.0 diopters (D) of sphere with and without astigmatic refractive errors up to -6.0 D at the spectacle plane".

Disclaimer for Hyperopia:

a. Approval of the premarket approval application is for the WaveLight ALLEGRETTO WAVE[R] Eye-Q Excimer Laser System to perform LASIK treatments in patients 18 years of age or older for the reduction or elimination of hyperopic refractive errors up to +6.0 diopters (D) of sphere with and without astigmatic refractive errors up to 5.0 D at the spectacle plane, with a maximum manifest refraction spherical equivalent (MRSE) of +6.0 D; and in patients with documented evidence of a stable manifest refraction defined as [?] 0.50 D of preoperative spherical equivalent shift over one year prior to surgery, exclusive of changes due to unmasking latent hyperopia.

b. LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), and other refractive surgeries.

c. Approval of the application is based on clinical trials in the United States with 290 eyes treated, of which 100 of 290 eligible eyes were followed for 12 months. Accountability at 3 months was 95.2%, at 6 months was 93.9%, and at 12 months was 69.9%.

d. The studies found that of the 212 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 6-month stability time point, 95.3% were corrected to 20/40 or better, and 67.5 % were corrected to 20/20 or better without spectacles or contact lenses.

e. The study showed that the following subjective patient adverse events were reported as "much worse" by at least 1% of the subjects (in order of increasing frequency) at 6 months post final treatment: glare from bright lights (3%); night driving glare (4.2%); light sensitivity (4.9%); visual fluctuations (6.1%); and halos (6.4%).

f. Long term risks of LASIK for hyperopia with and without astigmatism beyond 12 months have not been studied.

g. Note that the complete name for this ophthalmic laser is "WaveLight ALLEGRETTO WAVE[R] Eye-Q Excimer Laser System for laser assisted in situ keratomileusis (LASIK) treatments of hyperopic refractive errors up to +6.0 diopters (D) of with and without astigmatic refractive errors up to 5.0 D with a maximum manifest refraction spherical equivalent (MRSE) of +6.0 D".